Research and Markets has announced the addition of the "Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016" report to their offering.
Primary Progressive Multiple Sclerosis (PPMS) pipeline therapeutics constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. Our latest report Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Primary Progressive Multiple Sclerosis (PPMS) Primary-progressive multiple sclerosis (PPMS) is characterized by steady worsening of neurologic functioning, without any distinct relapses or periods of remission. Symptoms include problems in speech or swallowing, visual problems, fatigue and pain, bladder and bowel difficulties. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 2, 1 and 1 respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/mrjckb/primary
View source version on businesswire.com: http://www.businesswire.com/news/home/20160930005619/en/Business Wire
Last updated on: 30/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.